How to Buy Vir Biotechnology Stock
Vir Biotechnology Inc
Vir Biotechnology, Inc. , a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Vir Biotechnology stock last closed at $5.22, up 0% from the previous day, and has decreased 49.61% in one year. It has overperformed other stocks in the Biotechnology industry by 0.27 percentage points. Vir Biotechnology stock is currently +20.83% from its 52-week low of $4.32, and -63.88% from its 52-week high of $14.45.
At the moment, there are 138.24M VIR shares outstanding. The market value of VIR is $721.60M. In the last 24 hours, 893,000 VIR shares were traded.
How to Buy Vir Biotechnology Stock
Wondering how to invest in Vir Biotechnology stock? Here's how.
- Choose where to buy Vir Biotechnology stock: You need to choose a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you decide where to buy Vir Biotechnology stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Fund your brokerage account: Select your method of payment and add your info.
- Analyze Vir Biotechnology stock: The Vir Biotechnology ticker symbol is VIR. Is Vir Biotechnology stock a good investment? Should you buy shares of VIR? How do VIR's underlying business fundamentals look? Do top analysts think Vir Biotechnology is a good buy? Why has VIR's stock price moved recently? (Hint: Our stock research website can help you understand if VIR is a good stock to buy).
- Execute your VIR buy order: Decide if you will purchase VIR shares at the current market price or use a limit order to buy VIR shares at a particular price.
- Get the latest news on your VIR position: Create a watchlist to important updates regarding your position in Vir Biotechnology stock.
Step 1: Choose where to buy Vir Biotechnology stock
You need an online brokerage account to access the NASDAQ market and buy VIR stock.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global financial markets: From Technology to Energy, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the right brokerage, it's time to fill out some personal information so you are able to buy VIR stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to open a new trading account.
- Submit your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have finished signing up on one of the most highly reviewed stock trading apps, you need to deposit funds:
Check out the walkthrough below for more details depositing money into your new investment account.
Step 4: Analyze Vir Biotechnology stock
After you have chosen the best place to buy Vir Biotechnology stock, it's critical to analyze their stock prior to investing, so you truly comprehend the risk as well as the upside.
Vir Biotechnology Metrics
Vir Biotechnology Due Diligence Score
WallStreetZen was designed to help average investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on VIR's stock page.
How is VIR stock valued?
You can use many financial metrics, analyses, models, and charts to gauge VIR's true value.
Using relative valuations metrics:
- VIR could be undervalued based on its P/B ratio of 0.69x, relative to Biotechnology industry P/B ratio of 4.66x
You can access additional valuation analysis on VIR's stock here.
A look at VIR Cashflows and Balance Sheet
Pros:
- VIR has $889.81M in cash and short term investments. This is enough to cover its annual cash burn of $419.02M.
- Total VIR debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the VIR balance sheet.
- VIR has cash burn of 419016000. It has enough cash and short-term investments to cover this for at least one year.
- VIR has a low debt to equity ratio of 0.25.
- There are more short-term assets than long-term liabilities on the VIR balance sheet.
Cons:
- VIR profit margin has gone down from -677.7% to -2,769% in the past year.
Is Vir Biotechnology stock a Buy, Hold, or Sell, according to analysts?
Out of 7 Equities analysts who track VIR, the consensus analyst rating on Vir Biotechnology is a Strong Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
Most Recent VIR Analyst Upgrades/Downgrades
Michelle Gilson, a bottom 6% analyst from Morgan Stanley upgrades VIR to a strong buy rating and raises their VIR price target from $10.00 to $20.00, on Jan 9, 2025.
Eric Joseph, a bottom 3% analyst from JP Morgan maintains VIR with a hold rating and raises their VIR price target from $10.00 to $14.00, on Jan 9, 2025.
You can dive deeper into what analysts are forecasting on the Vir Biotechnology stock forecast page.
VIR Technical Indicators
VIR Growth Metrics
Last year, VIR revenue was $20.86M. During the last five year, VIR's revenue has gone up by 15.5% per year. This was slower than the Biotechnology industry average of 43.24%.
Find out more about VIR's earnings and revenue performance here.
Who is buying/selling VIR?
In the last 12 months, executives and large shareholders at VIR have sold more shares than they have bought.
Janet Napolitano, Director of VIR, was the latest VIR insider to sell. They sold $16,147.20 worth of VIR shares on Jun 2, 2025.
Get more info about who owns VIR shares here.
Can I rely on VIR as an income stream?
No, Vir Biotechnology doesn't provide an income stream by paying out dividends.
VIR Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your VIR buy order
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually the best for newer investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific price limit, place a limit order.
Click the Open Trade button and eToro will place the order.
If you want more info about investing in stocks on eToro, watch the helpful video below:
Step 6: Get the latest news on your VIR position
Now that you own some VIR shares, you'll want to keep up with your new stock purchase.
Put VIR on a watchlist to get the latest updates about your VIR stock.
VIR Feed
How to Buy Stock in Vir Biotechnology
To reiterate, here are the 6 steps to buy stock in Vir Biotechnology:
- Choose where to buy Vir Biotechnology stock
- Create your brokerage account
- Fund your brokerage account
- Analyze Vir Biotechnology stock
- Execute your VIR buy order
- Get the latest news on your VIR position
If you need a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you would like to track your investment in Vir Biotechnology, click below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.